Document Detail

Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.
MedLine Citation:
PMID:  22309979     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE Endocannabinoid systems are strongly implicated in the physiological control of appetite and eating behaviour, with cannabinoid CB(1) receptor agonists and antagonists, respectively, increasing or decreasing food intake. This study examined the acute actions of the putative endocannabinoid noladin ether on food intake and eating motivation, assessing how it affects the amount of work expended by animals to obtain food. EXPERIMENTAL APPROACH Non-deprived male rats were injected systemically with noladin ether to assess its acute effects on ad libitum feeding of a standard laboratory diet. Additionally, the effects of noladin on lever pressing for palatable food were determined using a progressive ratio (PR) operant paradigm. KEY RESULTS Noladin dose dependently increased 2 h food intake, with a significant effect over 1 h after a dose of 0.5 mg·kg(-1). In the PR test, this hyperphagic dose of noladin ether promoted sustained high rates of responding and significantly increased the total number of lever presses and break-point. These latter effects were prevented by pretreatment with 1.0 mg·kg(-1) of the selective CB(1) antagonist surinabant (SR147778), that alone had no effect on responding. CONCLUSIONS AND IMPLICATIONS This is the first report of hyperphagia induced by acute noladin administration, and the first description of behavioural actions in rats. Consistent with prevailing notions about the role of endocannabinoids in appetite, a hyperphagic dose of noladin markedly increased efforts expended by animals to obtain food. Thus, noladin exerts a specific action on eating motivation; possibly promoting eating by increasing the incentive value of food.
E K Jones; T C Kirkham
Related Documents :
18780199 - Effects of ramadan upon fluid and food intake, fatigue, and physical, mental, and socia...
3667029 - Use of quantified and frequency indices of vitamin a intake in a case-control study of ...
10197559 - Genetic effects on weight change and food intake in swedish adult twins.
18029499 - Fitting portion sizes in a self-administered food frequency questionnaire.
16138519 - Food offerings in marshfield area businesses: a survey conducted in collaboration with ...
6796609 - Utilization of diagnostic ultrasound in a controlled setting.
9751529 - A c-terminal fragment of agouti-related protein increases feeding and antagonizes the e...
1925289 - Houseflies (musca domestica) as mechanical vectors of shigellosis.
2886099 - Hypothalamic neurotransmitters in relation to normal and disturbed eating patterns.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  166     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-28     Completed Date:  2012-11-05     Revised Date:  2013-07-02    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1815-21     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
Department of Experimental Psychology, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Behavior, Animal / drug effects
Cannabinoid Receptor Modulators / pharmacology*
Eating / drug effects
Glycerides / pharmacology*
Hyperphagia / chemically induced*,  physiopathology
Motivation / drug effects
Piperidines / pharmacology
Pyrazoles / pharmacology
Receptor, Cannabinoid, CB1 / agonists*,  antagonists & inhibitors,  physiology
Grant Support
//Biotechnology and Biological Sciences Research Council
Reg. No./Substance:
0/Cannabinoid Receptor Modulators; 0/Endocannabinoids; 0/Glycerides; 0/Piperidines; 0/Pyrazoles; 0/Receptor, Cannabinoid, CB1; 0/noladin ether; 0/surinabant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophreni...
Next Document:  Chrysin abrogates cisplatin-induced oxidative stress, p53 expression, goblet cell disintegration and...